Skip to main content

Table 3 Summary of results from MMRM and LOCF_ANCOVA in duloxetine clinical trials.

From: The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

Outcome

Frequency of significant outcomes1MMRM LOCF_ANCOVA

P-value lower with MMRM LOCF_ANCOVA

Outcome significant with MMRM but not LOCF_ANCOVA

Outcome significant with LOCF_ANCOVA but not MMRM

HAMD 17

      

   Total score

9\12

6\12

9\12

1\12

3\12

0\12

   Core subscale

9\12

8\12

5\12

3\12

2\12

1\12

   Maier subscale

10\12

9\12

6\12

2\12

2\12

1\12

   Anxiety subscale

6\12

5\12

7\12

3\12

2\12

1\12

   Retardation subscale

8\12

6\12

6\12

3\12

4\12

2\12

   Sleep subscale

1\12

1\12

10\12

2\12

0\12

0\12

MADRS Total score

5\10

3\10

7\10

2\10

2\10

0\10

HAMA Total score

3\10

3\10

4\10

5\10

0\10

0\10

CGI-Severity

6\12

6\12

8\12

2\12

0\12

0\12

CGI-Improvement

1\2

1\2

2\2

0\2

0\2

0\2

PGI-Improvement

9\12

7\12

8\12

2\12

2\12

0\12

Somatic Symptom Inventory

      

   26-item Average score

2\10

2\10

7\10

3\10

0\10

0\10

   28-item Average score

3\10

2\10

7\10

3\10

1\10

0\10

VAS Pain Severity

      

   Overall pain

3\10

4\10

2\10

8\10

1\10

2\10

   Headaches

1\10

0\10

5\10

5\10

1\10

0\10

   Back pain

2\10

2\10

6\10

4\10

1\10

1\10

   Shoulder pain

2\10

1\10

3\10

6\10

2\10

1\10

   Daily activities

1\10

0\10

2\10

8\10

1\10

0\10

   Pain while awake

2\10

2\10

5\10

5\10

1\10

1\10

QLDS Total score

1\4

2/4

1\4

2\4

0\4

1\4

Totals

84\202

70\202

110\202

69\202

25\202

11\202

  1. 1. Some of the eight trials included more than one dose arm. Therefore, an individual outcome could be assessed in as many as 12 comparisons with placebo.